Cubist Systematic Strategies LLC Raises Stake in Mesoblast Limited (NASDAQ:MESO)

Cubist Systematic Strategies LLC increased its holdings in Mesoblast Limited (NASDAQ:MESO - Free Report) by 241.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,191 shares of the company's stock after purchasing an additional 24,870 shares during the quarter. Cubist Systematic Strategies LLC's holdings in Mesoblast were worth $697,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. R Squared Ltd bought a new stake in shares of Mesoblast in the 4th quarter valued at about $30,000. Barclays PLC acquired a new position in shares of Mesoblast in the fourth quarter worth approximately $38,000. Lindbrook Capital LLC boosted its holdings in Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock valued at $43,000 after acquiring an additional 901 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in Mesoblast in the fourth quarter valued at approximately $50,000. Finally, BNP Paribas Financial Markets increased its position in Mesoblast by 86,566.7% during the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock valued at $51,000 after purchasing an additional 2,597 shares during the period. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Piper Sandler restated an "overweight" rating and issued a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Mesoblast Trading Down 4.0%

Shares of Mesoblast stock traded down $0.47 on Wednesday, hitting $11.08. The company had a trading volume of 105,932 shares, compared to its average volume of 270,255. Mesoblast Limited has a 1 year low of $5.78 and a 1 year high of $22.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The stock has a 50 day moving average of $11.71 and a 200-day moving average of $13.89.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.